Indaptus Therapeutics, Inc 8-K, filed Jun 22, 2021
Indaptus Therapeutics, Inc. (INDP)
About this 8-K
Indaptus Therapeutics, Inc filed this 8-K on June 22, 2021, reporting on events of June 21, 2021.
Items reported
- Item 8.01: Other events
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,DC 20549
FORM8-K
CURRENTREPORT
Pursuantto Section 13 or 15(d) of
TheSecurities Exchange Act of 1934
Dateof Report (Date of earliest event reported)
June21, 2021
INTECPARENT, INC.
(Exactname of registrant as specified in its charter)
| Delaware | 333-255389 | 86-3158720 |
|---|---|---|
| (State<br> or other jurisdiction<br><br> of incorporation) | (Commission<br> <br><br> File Number) | (IRS<br> Employer<br><br> Identification No.) |
| 12 Hartom St.<br><br> <br>Har Hotzvim | ||
| --- | --- | |
| Jerusalem, Israel | 9777512 | |
| (Address<br> of principal executive offices) | (Zip<br> Code) | |
| + 972-2-586-4657 | ||
| (Registrant’s<br> telephone number, including area code)<br><br> <br><br><br> <br><br><br> <br>(Former<br> name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [X] | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [ ] | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
|---|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item8.01. Other Events.
On June 21, 2021, Intec Pharma Ltd. (the “Intec Israel”) held a special meeting of shareholders (the “Special Meeting”) to consider seven proposals related to Intec Israel’s merger with Decoy Biosystems, Inc., a Delaware corporation (“Decoy”), in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2021 among the Company, Intec Parent, Inc., a Delaware corporation and wholly-owned subsidiary of Intec Israel (the “Company”), Dillon Merger Subsidiary Inc., a Delaware corporation, Domestication Merger Sub, Ltd., an Israeli company and a wholly-owned subsidiary of the Company, and Decoy. Each of Intec Israel’s proposals was approved at the Special Meeting by the requisite vote of Intec Israel’s shareholders as described in the Current Report on Form 8-K filed by Intec Israel on June 22, 2021.
| 2 |
| --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 22, 2021
| INTEC PARENT, INC. | |
|---|---|
| By: | /s/ Jeffrey Meckler |
| Jeffrey<br> Meckler | |
| President |
| 3 |
| --- |